You can buy Lucilazer at the lowest price in the online pharmacy Nextgen.ooo . Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations. It was approved by the FDA on August 19, 2024.
 
Lazertinib is a kinase inhibitor of mutant epidermal growth factor receptor (EGFR). It targets EGFR single (Ex19del, L858R, T790M) and double (Ex19del/T790M and L858R/T790M) mutations. The inhibition of wild-type EGFR by lazertinib is less selective and potent. Lazertinib irreversibly inhibits EGFR by forming a covalent bond to the Cys797 residue in the ATP-binding site of the EGFR kinase domain.3 It blocks the EGFR downstream signalling cascades - including the phosphorylation of EGFR, AKT and ERK - and promotes apoptosis of EGFR-mutant lung cancer cells.